Valuation: Genome & Company

Market Cap 178B 128M 112M 105M 95.7M 179M 12.28B 180M 1.26B 487M 6.25B 481M 471M 20.15B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 160B 115M 100M 94.7M 86.08M 161M 11.05B 162M 1.13B 438M 5.62B 433M 423M 18.12B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.14%
Yield 2024 *
-
Yield 2025 -
04-13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
04-03 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
03-13 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
22/09/25 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
21/08/25 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
10/07/25 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
28/04/25 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
24/04/25 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
24/04/25 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
24/04/25 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
19/07/24 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
17/07/24 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24/01/24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-3.41%
1 week+2.88%
Current month-9.59%
1 month-26.52%
3 months-39.38%
6 months-60.57%
Current year-50.65%
1 week 2,925
Extreme 2925
3,595
1 month 2,925
Extreme 2925
4,520
Current year 2,925
Extreme 2925
10,180
1 year 2,470
Extreme 2470
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
23,050
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 24/09/2015
Chief Executive Officer 55 24/09/2015
Director TitleAgeSince
Director/Board Member 55 24/09/2015
Director/Board Member 53 24/09/2015
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap. Importance
5/9/25 A Don

Chief Executive Officer

100,000 0.3217%
5/9/25 A Free

Director

40,000 0.1287%
5/9/25 A Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
-3.41%+2.88%+24.13%-57.27% 133M
+0.11%+1.98%-0.04%+9.69% 46.18B
-1.12%+3.54%+42.71%+25.84% 44.35B
-3.04%-6.10%+335.86%+501.23% 42.21B
-0.74%+2.64%+5.61%+75.14% 40.19B
-0.50%-0.77%+11.86%+40.41% 29.83B
-0.46%+5.00%+23.00%+118.70% 17.17B
-0.97%-9.38% - - 15.7B
-0.57%+7.78%+21.76%+38.08% 15.32B
-3.28%-0.95%-6.34%-37.29% 13.09B
Average -1.40%+2.19%+50.95%+79.39% 26.42B
Weighted average by Cap. -1.11%+1.64%+69.61%+117.12%

Financials

2024 2025
Net sales 27.74B 20.03M 17.45M 16.45M 14.95M 27.99M 1.92B 28.11M 197M 76.05M 976M 75.19M 73.52M 3.15B 24.59B 17.75M 15.47M 14.58M 13.25M 24.81M 1.7B 24.91M 174M 67.39M 865M 66.63M 65.16M 2.79B
Net income -20.11B -14.52M -12.65M -11.93M -10.84M -20.29M -1.39B -20.37M -143M -55.13M -708M -54.5M -53.3M -2.28B -6.43B -4.64M -4.04M -3.81M -3.46M -6.49M -445M -6.51M -45.6M -17.62M -226M -17.42M -17.03M -729M
Net Debt -48.91B -35.31M -30.76M -29M -26.36M -49.35M -3.38B -49.54M -347M -134M -1.72B -133M -130M -5.55B -17.86B -12.9M -11.24M -10.59M -9.63M -18.02M -1.24B -18.09M -127M -48.96M -628M -48.41M -47.34M -2.03B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
18/09/26 ₩3,395.00 -3.41% 2,121,833
17/09/26 ₩3,515.00 +5.56% 383,702
16/09/26 ₩3,330.00 -2.20% 300,849
15/09/26 ₩3,405.00 +7.24% 968,364
14/09/26 ₩3,175.00 -2.31% 90,516
  1. Stock Market
  2. Stocks
  3. A314130 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!